甲氨蝶呤治疗银屑病患者与皮肤黑色素瘤风险:巢式病例对照研究
BACKGROUND: Cutaneous malignant melanoma (CMM) is a highly immunogenic tumour. Patients with an impaired immune system have an enhanced risk for CMM and a worse prognosis.…
要点
- 未观察到甲氨蝶呤累积剂量与皮肤黑色素瘤风险之间的剂量反应关联。
- 该结果提示皮肤科医生使用甲氨蝶呤治疗银屑病时无需过度担心黑色素瘤风险。
核心结论
- 在瑞典银屑病患者中,甲氨蝶呤的使用与皮肤黑色素瘤风险增加无关。
研究设计与样本
- 采用巢式病例对照研究设计,数据来自瑞典登记数据库。
- 按年龄(相同出生年)和性别为每例病例匹配10例随机选取的无癌银屑病患者作为对照,共3950例对照。
主要发现
- 395例皮肤黑色素瘤患者中97例(25%)曾开具甲氨蝶呤处方;3950例对照中相应为954例(24%)。
- 未观察到甲氨蝶呤累积剂量与皮肤黑色素瘤风险之间存在剂量反应关联的迹象。
临床怎么用
- 皮肤科医生使用甲氨蝶呤治疗银屑病患者时,无需因担心皮肤黑色素瘤风险而改变临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous malignant melanoma (CMM) is a highly immunogenic tumour. Patients with an impaired immune system have an enhanced risk for CMM and a worse prognosis. Methotrexate (MTX) is an anti-inflammatory and immunosuppressive drug frequently used to treat patients with psoriasis. An association between MTX and risk of CMM has previously been demonstrated in patients with rheumatoid arthritis. OBJECTIVES: To investigate whether MTX increases the risk of CMM among patients with psoriasis. METHODS: A nested case-control investigation from a Swedish cohort of patients with psoriasis was conducted. Data were obtained from available Swedish registers and included 395 patients with psoriasis who had previously been cancer-free and had a first CMM in the time period from 1 January 2010 to 31 December 2016. A total of 10 randomly selected cancer-free patients with psoriasis were matched per case with respect to age (same birth year) and sex. The accumulated MTX doses in both groups were obtained. Crude odds ratios (ORs) for the proportion of MTX in the respective group were calculated using conditional logistic regression analyses. RESULTS: Of 395 patients with psoriasis who had CMM, 97 (25%) had filled a prescription of MTX; of 3950 controls, the corresponding number was 954 (24%). In a conditional logistic regression analysis, no association between MTX exposure (ever use) and risk for CMM was observed (OR 1·0, 95% confidence interval 0·8-1·3). Moreover, no indication of a dose-response association was observed. CONCLUSIONS: In this Swedish nested case-control study, the use of MTX was not associated with an enhanced risk for CMM. These findings are reassuring for dermatologists in everyday clinical practice. What is already known about this topic? Methotrexate (MTX) treatment has been linked to an increased risk for cutaneous malignant melanoma (CMM) in an Australian cohort of patients with rheumatoid arthritis. In a previous retrospective Swedish cohort investigation, patients who had exclusively been prescribed MTX by a dermatologist did not have an enhanced risk for CMM compared with MTX-unexposed individuals. Nevertheless, this cohort did not specifically include patients with psoriasis. What does this study add? This Swedish nested case-control investigation included 395 previously cancer-free patients with psoriasis who had CMM (cases) and 3950 matched cancer-free patients with psoriasis (controls). No association between MTX exposure and risk for CMM in patients with psoriasis was observed. The results are reassuring for dermatologists using MTX to treat patients with psoriasis. Linked Comment: Haugaard and Egeberg. Br J Dermatol 2020; 183:608-609.
引用
- Polesie S, Gillstedt M, Paoli J, et al. Methotrexate treatment for patients with psoriasis and risk of cutaneous melanoma: a nested case-control study. Br J Dermatol. 2020. PMID: 31981364. doi:10.1111/bjd.18887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。